Incidence and Relative Risk of Peripheral Neuropathy in Cancer Patients Treated with Eribulin: a Meta-analysis

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Jan 18

PMID 29340112

Citations 3

Authors

Ling Peng

Yun Hong

Xianghua Ye

Peng Shi

Junyan Zhang

Yina Wang

Qiong Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Eribulin is a microtubule inhibitor, which is approved for the treatment of breast cancer. Peripheral neuropathy has been reported in the studies of eribulin, but the incidence and relative risk (RR) of eribulin-associated peripheral neuropathy varied greatly in cancer patients. The purpose of this meta-analysis was to determine the overall incidence and RR of eribulin-associated peripheral neuropathy in cancer patients.

Materials And Methods: Pubmed database and Embase and abstracts presented at the American Society of Clinical Oncology (ASCO) meetings were systematically reviewed for primary studies. Eligible studies included prospective clinical trials and expanded access programs of cancer patients treated with eribulin. Statistical analyses were performed to calculate the incidences, RRs, and 95% confidence intervals (CIs).

Results: Altogether, 4,849 patients from 19 clinical trials were selected for this meta-analysis. The incidences of all-grade and high-grade peripheral neuropathy were 27.5% (95% CI: 23.3-32.4%) and 4.7% (95% CI: 3.6-6.2%), respectively. The relative risks of peripheral neuropathy of eribulin compared to control were increased for all-grade (RR = 1.89, 95% CI: 1.10-3.25) but not statistically significant for high-grade (RR = 2.98, 95% CI: 0.71-12.42).

Conclusions: The use of eribulin is associated with an increased incidence of peripheral neuropathy. The RR is increased for all-grade peripheral neuropathy.

Citing Articles

Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study.

Schmidt M, Hesse T, Hoffmann O, Heinrich B, Park-Simon T, Grischke E Cancers (Basel). 2025; 17(3).

PMID: 39941823 PMC: 11815746. DOI: 10.3390/cancers17030457.

Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.

La Verde N, Damia G, Garrone O, Santini D, Fabi A, Ciccarese M Breast Cancer Res. 2022; 24(1):71.

PMID: 36307826 PMC: 9615373. DOI: 10.1186/s13058-022-01560-w.

First-line bevacizumab and eribulin combination therapy for HER2-negative metastatic breast cancer: Efficacy and safety in the GINECO phase II ESMERALDA study.

Hardy-Bessard A, Brocard F, Clatot F, Lortholary A, You B, Grenier J Breast. 2020; 54:256-263.

PMID: 33188992 PMC: 7672314. DOI: 10.1016/j.breast.2020.09.011.

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study.

Tsurutani J, Sakata Y, Matsuoka T Breast Cancer. 2018; 26(2):235-243.

PMID: 30324551 PMC: 6394617. DOI: 10.1007/s12282-018-0919-8.

References

Vahdat L, Garcia A, Vogel C, Pellegrino C, Lindquist D, Iannotti N . Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. Breast Cancer Res Treat. 2013; 140(2):341-51. PMC: 3732762. DOI: 10.1007/s10549-013-2574-2. View

Schoffski P, Chawla S, Maki R, Italiano A, Gelderblom H, Choy E . Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016; 387(10028):1629-37. DOI: 10.1016/S0140-6736(15)01283-0. View

Zintzaras E, Ioannidis J . Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol. 2004; 28(2):123-37. DOI: 10.1002/gepi.20048. View

Cortes J, OShaughnessy J, Loesch D, Blum J, Vahdat L, Petrakova K . Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377(9769):914-23. DOI: 10.1016/S0140-6736(11)60070-6. View

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

Gitlitz B, Tsao-Wei D, Groshen S, Davies A, Koczywas M, Belani C . A phase II study of halichondrin B analog eribulin mesylate (E7389) in patients with advanced non-small cell lung cancer previously treated with a taxane: a California cancer consortium trial. J Thorac Oncol. 2011; 7(3):574-8. PMC: 3288403. DOI: 10.1097/JTO.0b013e31823f43ca. View

Aogi K, Iwata H, Masuda N, Mukai H, Yoshida M, Rai Y . A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer. Ann Oncol. 2011; 23(6):1441-8. DOI: 10.1093/annonc/mdr444. View

Kawai A, Araki N, Naito Y, Ozaki T, Sugiura H, Yazawa Y . Phase 2 study of eribulin in patients with previously treated advanced or metastatic soft tissue sarcoma. Jpn J Clin Oncol. 2017; 47(2):137-144. PMC: 5943671. DOI: 10.1093/jjco/hyw175. View

Jordan M, Kamath K, Manna T, Okouneva T, Miller H, Davis C . The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther. 2005; 4(7):1086-95. DOI: 10.1158/1535-7163.MCT-04-0345. View

10.

Stubblefield M, Burstein H, Burton A, Custodio C, Deng G, Ho M . NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009; 7 Suppl 5:S1-S26. DOI: 10.6004/jnccn.2009.0078. View

11.

Spira A, Iannotti N, Savin M, Neubauer M, Gabrail N, Yanagihara R . A phase II study of eribulin mesylate (E7389) in patients with advanced, previously treated non-small-cell lung cancer. Clin Lung Cancer. 2011; 13(1):31-8. DOI: 10.1016/j.cllc.2011.06.010. View

12.

McIntyre K, OShaughnessy J, Schwartzberg L, Gluck S, Berrak E, Song J . Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer. Breast Cancer Res Treat. 2014; 146(2):321-8. PMC: 4085472. DOI: 10.1007/s10549-014-2923-9. View

13.

Watanabe J, Ito Y, Ohsumi S, Mizutani M, Tashiro H, Sakurai K . Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study. Invest New Drugs. 2017; 35(6):791-799. PMC: 5694520. DOI: 10.1007/s10637-017-0486-4. View

14.

Park Y, Kim T, Im Y, Lee K, Park I, Sohn J . Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. Cancer Res Treat. 2016; 49(2):423-429. PMC: 5398406. DOI: 10.4143/crt.2016.191. View

15.

Schoffski P, Ray-Coquard I, Cioffi A, Bui N, Bauer S, Hartmann J . Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol. 2011; 12(11):1045-52. DOI: 10.1016/S1470-2045(11)70230-3. View

16.

Hershman D, Lacchetti C, Dworkin R, Smith E, Bleeker J, Cavaletti G . Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2014; 32(18):1941-67. DOI: 10.1200/JCO.2013.54.0914. View

17.

Peng L, Bu Z, Ye X, Zhou Y, Zhao Q . Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl). 2015; 26(5). DOI: 10.1111/ecc.12407. View

18.

Yardley D, Reeves J, Dees E, Osborne C, Paul D, Ademuyiwa F . Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clin Breast Cancer. 2016; 16(6):471-479.e1. DOI: 10.1016/j.clbc.2016.07.005. View

19.

Friedrich J, Adhikari N, Beyene J . Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol. 2007; 7:5. PMC: 1783664. DOI: 10.1186/1471-2288-7-5. View

20.

Aftimos P, Polastro L, Ameye L, Jungels C, Vakili J, Paesmans M . Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial. Eur J Cancer. 2016; 60:117-24. DOI: 10.1016/j.ejca.2016.03.010. View